GBM Clinical Trial
Official title:
A Prospective Phase I/II Clinical Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM.
This phase I/II clinical trial is intended to investigate the efficacy and safety of SVZ irradiation with postoperative radiotherapy in patients with GBM.
This study is a single-center, single-arm, phase I/II clinical study. It is intended to include treatment-naïve patients with histologically or cytologically confirmed glioblastoma who have received only radical surgical treatment according to the investigator's assessment. After signing the informed consent, the patient will be selected to meet the inclusion criteria and will receive postoperative adjuvant radiotherapy combined with temozolomide chemotherapy, followed by 6 cycles of temozolomide maintenance therapy. During the follow-up process, patients included in the study can withdraw from this study if they are judged by MRI examination to have disease progression, unacceptable toxic reactions occur, or the subject decides to withdraw from the study. The subsequent specific treatment plan will be discussed with the MDT and fully discussed with the patient and family members. Implement after communication. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06147505 -
Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
| Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
| Completed |
NCT01478178 -
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
|
Phase 1/Phase 2 | |
| Terminated |
NCT03119064 -
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05686798 -
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
|
Phase 1 | |
| Recruiting |
NCT03758014 -
Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients
|
Phase 2/Phase 3 | |
| Terminated |
NCT01205334 -
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00114309 -
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
|
Phase 2 | |
| Not yet recruiting |
NCT03746288 -
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
|
Phase 2 | |
| Terminated |
NCT04681677 -
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
|
Phase 2 | |
| Completed |
NCT01856933 -
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
|
Phase 2 | |
| Terminated |
NCT04763031 -
Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT
|
N/A | |
| Completed |
NCT00107003 -
GW572016 to Treat Recurrent Malignant Brain Tumors
|
Phase 2 | |
| Completed |
NCT03426891 -
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Recruiting |
NCT04115761 -
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
|
Phase 2 | |
| Recruiting |
NCT05954858 -
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
|
N/A | |
| Not yet recruiting |
NCT06388733 -
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
|
Phase 3 | |
| Recruiting |
NCT02861898 -
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 |